Group 1 - Verizon Communications reported quarterly earnings of $1.22 per share, exceeding the Zacks Consensus Estimate of $1.18 per share, and up from $1.15 per share a year ago, representing an earnings surprise of +3.39% [1] - The company posted revenues of $34.5 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.76%, compared to year-ago revenues of $32.8 billion [2] - Over the last four quarters, Verizon has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2 - The stock's immediate price movement will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3][4] - Verizon shares have increased about 2.1% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The current consensus EPS estimate for the coming quarter is $1.20 on revenues of $33.88 billion, and for the current fiscal year, it is $4.68 on revenues of $137.15 billion [7] Group 3 - The Zacks Industry Rank indicates that the Wireless National industry is currently in the bottom 27% of over 250 Zacks industries, which may impact Verizon's stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Verizon was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it will perform in line with the market in the near future [6]

Core Insights - Badger Meter, Inc. (BMI) is positioned favorably for an upcoming earnings report, with positive trends indicating a potential earnings beat [1][5] Earnings Estimates - Recent earnings estimate revisions for BMI have been favorable, suggesting analysts are optimistic about the company's performance [2] - The Most Accurate Estimate for the upcoming quarter is $1.28 per share, compared to the broader Zacks Consensus Estimate of $1.21 per share, indicating a recent upward revision by analysts [3] Earnings ESP - BMI has a Zacks Earnings ESP of +5.61%, which is a positive indicator heading into earnings season [3] - A positive Zacks Earnings ESP has historically led to positive surprises and outperformance in the market, with a nearly 70% success rate in producing positive surprises [4] Investment Consideration - With a Zacks Rank of 3 (Hold) and a positive Earnings ESP, BMI may be a stock worth considering for investors ahead of the earnings report [5]

Core Viewpoint - Fiserv (FI) shares have increased by 1.4% over the past month, closing at $165.74, with a potential upside of 31.6% based on Wall Street analysts' mean price target of $218.09 [1] Group 1: Price Targets and Analyst Estimates - The mean estimate consists of 34 short-term price targets with a standard deviation of $31.63, indicating variability among analysts; the lowest estimate is $125.00 (24.6% decline), while the highest is $268.00 (61.7% increase) [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price direction, serving as a starting point for further research [9] Group 2: Earnings Estimates and Market Sentiment - There is growing optimism among analysts regarding Fiserv's earnings prospects, supported by a consensus of higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 0.2%, with four estimates moving higher and no negative revisions [12] - Fiserv holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]

Group 1 - Cleveland-Cliffs reported a quarterly loss of $0.5 per share, better than the Zacks Consensus Estimate of a loss of $0.68, and compared to earnings of $0.11 per share a year ago, representing an earnings surprise of +26.47% [1] - The company posted revenues of $4.93 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.62%, but down from $5.09 billion year-over-year [2] - Cleveland-Cliffs shares have increased approximately 0.9% since the beginning of the year, while the S&P 500 has gained 7.1% [3] Group 2 - The earnings outlook for Cleveland-Cliffs is mixed, with the current consensus EPS estimate for the coming quarter at -$0.20 on revenues of $4.97 billion, and -$1.69 on revenues of $19.46 billion for the current fiscal year [7] - The Zacks Industry Rank indicates that the Steel - Producers industry is currently in the bottom 14% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] Group 3 - Cleveland-Cliffs has surpassed consensus EPS estimates only once in the last four quarters, while it has topped consensus revenue estimates three times during the same period [2][6] - The estimate revisions trend for Cleveland-Cliffs was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Group 1 - Enliven Therapeutics, Inc. (ELVN) shares have increased by 8.2% over the past four weeks, closing at $23.34, with a mean price target of $41 indicating a potential upside of 75.7% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $6.74, where the lowest estimate of $33.00 suggests a 41.4% increase, and the highest estimate of $52.00 indicates a potential surge of 122.8% [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases, as the Zacks Consensus Estimate for the current year has risen by 4.6% over the past month [11][12] Group 2 - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside [13] - While consensus price targets may not be reliable indicators of the extent of gains, they can provide a directional guide for price movement [14]

Core Viewpoint - First Financial Bankshares (FFIN) reported quarterly earnings of $0.47 per share, exceeding the Zacks Consensus Estimate of $0.45 per share, and showing an increase from $0.37 per share a year ago, indicating a positive earnings surprise of +4.44% [1][2] Financial Performance - The company posted revenues of $159.53 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.52%, compared to $137.11 million in the same quarter last year [2] - Over the last four quarters, First Financial has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance and Outlook - First Financial shares have increased by approximately 0.8% since the beginning of the year, while the S&P 500 has gained 6.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $0.47 on revenues of $157.2 million, and for the current fiscal year, it is $1.80 on revenues of $618.8 million [7] - The estimate revisions trend for First Financial was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Banks - Southwest industry, to which First Financial belongs, is currently ranked in the top 17% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - U.S. Bancorp reported quarterly earnings of $1.11 per share, exceeding the Zacks Consensus Estimate of $1.07 per share, and showing an increase from $0.98 per share a year ago, indicating a positive earnings surprise of +3.74% [1][2] Financial Performance - The company posted revenues of $7 billion for the quarter ended June 2025, which was 0.84% below the Zacks Consensus Estimate, compared to $6.84 billion in the same quarter last year [2] - Over the last four quarters, U.S. Bancorp has surpassed consensus EPS estimates four times but has only topped revenue estimates once [2] Stock Performance - U.S. Bancorp shares have declined approximately 4.5% year-to-date, contrasting with the S&P 500's gain of 6.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.08 on revenues of $7.17 billion, and for the current fiscal year, it is $4.30 on revenues of $28.41 billion [7] - The trend of earnings estimate revisions is mixed ahead of the earnings release, which may influence future stock performance [6] Industry Context - The Banks - Major Regional industry, to which U.S. Bancorp belongs, is currently ranked in the top 6% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

Core Viewpoint - Rapt Therapeutics (RAPT) shares have increased by 5.8% recently, closing at $8.72, with a mean price target of $24.75 suggesting a potential upside of 183.8% [1][2] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $17.35, indicating variability among analysts [2] - The lowest estimate is $8.00, suggesting an 8.3% decline, while the highest estimate is $48.00, indicating a potential surge of 450.5% [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about RAPT's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 24.1%, with one estimate moving higher and no negative revisions [12] - RAPT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][10] - Price targets can often be inflated due to business incentives, leading to overly optimistic projections [8]

Group 1 - Harmony Biosciences Holdings, Inc. (HRMY) shares have increased by 5.5% over the past four weeks, closing at $34.71, with a mean price target of $49.7 indicating a potential upside of 43.2% [1] - The mean estimate consists of 10 short-term price targets with a standard deviation of $11.66, where the lowest estimate is $31.00 (10.7% decline) and the highest is $70.00 (101.7% increase) [2] - Analysts show a consensus that HRMY will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for HRMY has increased by 0.2% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - HRMY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Group 1: United Airlines (UAL) - United Airlines shares increased by 14.3% to close at $91.67, driven by higher trading volume compared to typical sessions [1] - The stock's performance contrasts with a 2% gain over the past four weeks [1] - The consensus EPS estimate for United has been revised 5.4% lower in the last 30 days, indicating a negative trend in earnings estimate revisions [4] Group 2: Airline Industry - Optimism in the airline industry was fueled by Delta Air Lines' better-than-expected Q2 2025 earnings results, which included earnings and revenue beats and the restoration of full-year guidance [2] - Delta Air Lines is expected to report quarterly earnings of $3.75 per share, reflecting a year-over-year decline of 9.4%, with revenues projected at $15.31 billion, a 2.2% increase from the previous year [2] - Corporacion America Airports, another airline stock, has seen a consensus EPS estimate change of -1.9% to $0.47, but this represents a significant year-over-year increase of 51.6% [6]